Coverage
-
January 06, 2022
Generic-drug makers have spent more than a year voicing concerns that the Federal Circuit's holding in GlaxoSmithKline v. Teva threatened their ability to sell generic drugs that leave patent-protected indications off the label, but a Delaware federal judge this week quelled some of those fears by quickly throwing out a challenge to such "skinny labels."
3 other articles on this case.
View all »